market-access
(4)
Amy Mahery Learned the Business by Moving Toward the Hard Parts
Her career began with a rugby conversation in an airport lounge. Two decades later, the Moderna marketing chief still treats curiosity, range and access to information as operating tools.
Girisha Fernando
Girisha Fernando is the CEO and co-founder of Lyfegen, a Basel- and Boston-based healthtech company building software that helps payers, hospitals, pharma companies and medical device makers manage value-based drug pricing, access and rebate agreements. After nearly a decade at Roche in market access, pricing and IT, he left in 2018 to build technology that ties the price of medicine to how well it actually works for patients. He splits his time between Switzerland and New York as Lyfegen pushes into the US market.
Mohan Purushothaman
Mohan Purushothaman is the co-founder, chairman, and CEO of Progentec Diagnostics, an Oklahoma City company building blood tests and digital tools that aim to predict autoimmune disease flares before they happen. He came to diagnostics by an unusual route: a Johns Hopkins Ph.D. focused on pharmaceutical pricing, a Harvard research fellowship, five years inside Roche, and a pricing-software practice he built and sold to Alliance Life Sciences. In 2014 he turned that commercial instinct toward lupus, partnering with the Oklahoma Medical Research Foundation, and in 2020 raised a $5M Series A led by Plains Venture Partners to bring the aiSLE DX flare-prediction platform and the LupusCorner patient community to market.
Mike Fitzgibbons
Mike Fitzgibbons is the CEO and Founder of Claritas Rx, a South San Francisco-based healthtech company that uses AI and real-world patient-level data to help biopharmaceutical companies track, understand, and support patients across the specialty drug treatment journey. Founded in 2011, Claritas Rx serves 20+ rare and specialty therapeutic areas and has appeared on Inc.'s 2025 list of America's Fastest-Growing Private Companies. Before founding Claritas Rx, Fitzgibbons spent seven years at Morgan Stanley as an equity research analyst covering pharma services and drug distribution, then joined Genentech where he worked on pricing strategy and led the Avastin marketing team - experiences that directly shaped his conviction that patient-level data, not aggregated reports, is what biopharma companies actually need.